Tirzepatide Hub · formblends network
Everything tirzepatide beyond the introduction: a titration planner that lays out label-minimum dates, a units-to-mg converter for compounded vials, the missed-dose and day-change rules from the label, adverse reaction rates by dose from the Zepbound and Mounjaro labels, Mounjaro versus Zepbound, SURMOUNT trial numbers with PubMed ids, and a self-pay cost tracker using Lilly's dated prices.
Interactive
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
Label-minimum dates for every 2.5 mg step, from your start day to your prescribed maintenance dose.
Insulin-syringe units for a prescribed mg dose at your vial's concentration, and back again.
The 96-hour missed-dose window and the 72-hour day-change rule, applied to your times.
Label adverse reaction rates for your dose arm next to placebo, with the excess and where you are in escalation.
Lilly's dated self-pay prices by strength, per injection, per mg and per year, with a first-year escalation total.
Reading
Written for people doing the arithmetic themselves: where the mistakes happen, and how to check your own work.
Compare
Where the two tirzepatide labels agree (dosing, missed-dose rules, strengths, presentations, storage) and where they differ (indications, approval dates, trial populations, adverse reaction tables, pediatric use).
Updated September 4, 2026
Compare
SURMOUNT-5 compared the two drugs directly over 72 weeks. The weight and waist results, the thresholds, the open-label caveat, and how the dosing schedules and prices line up.
Updated September 4, 2026
Costs
The list price at launch, the LillyDirect vial prices at each change since August 2024, the KwikPen self-pay tiers, and a cost tracker that turns them into cost per injection, per milligram and per year.
Updated September 4, 2026
Guides
What the Zepbound and Mounjaro labels say about starting at 2.5 mg, moving up in 2.5 mg steps, and which doses count as maintenance. Plus a planner that turns the rules into calendar dates.
Updated September 4, 2026
Guides
Exactly what the Zepbound and Mounjaro labels say about a late dose, a skipped dose, and changing your injection day, with worked examples and a helper that applies the rules to your times.
Updated September 4, 2026
Guides
Why a compounded tirzepatide dose has to be recalculated for every vial, how insulin-syringe units relate to milligrams, what the brand concentrations are, and what FDA says about dosing errors.
Updated September 4, 2026
Browse
Tirzepatide has two brand labels (Mounjaro for type 2 diabetes since May 13, 2022; Zepbound for weight reduction since November 8, 2023 and for obstructive sleep apnea since December 20, 2024), six strengths, four presentations, a 20-week label-minimum escalation, a 96-hour missed-dose window, a 72-hour day-change rule and a price list that Lilly has changed three times since August 2024. Each of those facts is small. Together they generate most of the questions people actually have. This site answers them one page at a time, with the label section or PubMed id next to every number.
It will not tell you what dose to take or when to move up. The tools take the dose from your prescription and do arithmetic on dates, volumes and prices. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; where a page discusses it, that is said plainly. There are no reviews, testimonials, or star ratings here, and no clinician bylines. The byline is the FormBlends editorial team, which also runs formblends.com, a GLP-1 program with a commercial interest disclosed on every page.
From the FormBlends network